Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports

BACKGROUND: Renal cell carcinoma represents 3–5% of adult malignant tumors. Metastases are found in 30–40% of patients and brain metastases occurred in more than 10% of them. Despite significant progress in medical treatment, patients with brain metastases still have a limited survival. Cabozantinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Négrier, Sylvie, Moriceau, Guillaume, Attignon, Valéry, Haddad, Véronique, Pissaloux, Daniel, Guerin, Nicole, Carrie, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260776/
https://www.ncbi.nlm.nih.gov/pubmed/30474572
http://dx.doi.org/10.1186/s13256-018-1875-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260776/
https://www.ncbi.nlm.nih.gov/pubmed/30474572
http://dx.doi.org/10.1186/s13256-018-1875-9

Ejemplares similares